Development · 10 Nov 2026
DIVISLAB, full dossier8 publishers have reported this development. Each act of reporting is below, cited.
Divi's Laboratories achieved a profit surge of 63.6% year-on-year for the September quarter of FY27, with operational revenue increasing by 35.4% to Rs 3,676 crore.
Divi's Laboratories' consolidated net profit jumped nearly 64% year-on-year to ₹ 1,127 crore in the September quarter of FY27.
Divi's Laboratories Ltd posted a 63.57 per cent rise in net profit to ₹1,127 crore in the September quarter.
Divis Laboratories reported a 64% rise in Q2 net profit to Rs 1127 crore.
Divi's Laboratories reported a 64 percent year-on-year increase in its September quarter net profit.
Divi's Laboratories' consolidated net profit rose 64% year-on-year to ₹1,127 crore in Q2FY27, compared with ₹689 crore in the corresponding quarter of the previous fiscal year.
Divi's Laboratories Ltd.'s net profit saw a 64% uptick to Rs 1,127 crore, according to the second quarter results for the fiscal 2026-27.
Divi's Laboratories shares rose.
9 Nov 2026 · 1 publisher
9 Nov 2026 · 1 publisher
9 Nov 2026 · 1 publisher
9 Nov 2026 · 1 publisher
The US Food and Drug Association approved Foundayo for weight-loss on April 1, 2026.
19 Oct 2026 · 1 publisher
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.